Search results
Results from the WOW.Com Content Network
An epithelial sodium channel blocker is a sodium channel blocker that is selective for the epithelial sodium channel. An example is amiloride , which is used in the treatment of hypertension . [ 1 ]
Sodium channel blockers are also used as local anesthetics and anticonvulsants. [5] Sodium channel blockers have been proposed for use in the treatment of cystic fibrosis, [6] but current evidence is mixed. [7] It has been suggested that the analgesic effects of some antidepressants may be mediated in part via sodium channel blockade. [8]
For example, TTX can bind and inactivate voltage-gated sodium channels, despite the fact that TTX is much larger and chemically different than sodium ions. Given the disparities in size and chemical properties between TTX and a sodium ion, this is an example of structure being used to block usually specific channels.
A channel opener, also known as a channel activator, is a type of drug which facilitates ion flow through ion channels. They include the following: Potassium channel openers; Calcium channel openers; Sodium channel openers; Chloride channel openers
Examples of targets for modulators include: Voltage-gated ion channels. Calcium channel: see also Calcium channel blocker, Calcium channel opener; Potassium channel: see also Potassium channel blocker, Potassium channel opener; Sodium channel: see also Sodium channel blocker, Sodium channel opener
The epithelial sodium channel (ENaC), (also known as amiloride-sensitive sodium channel) is a membrane-bound ion channel that is selectively permeable to sodium ions (Na +).It is assembled as a heterotrimer composed of three homologous subunits α or δ, β, and γ, [2] These subunits are encoded by four genes: SCNN1A, SCNN1B, SCNN1G, and SCNN1D.
Procainamide (PCA) is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias.It is a sodium channel blocker of cardiomyocytes; thus it is classified by the Vaughan Williams classification system as class Ia.
key:zyscouxlbxggim-uhfffaoysa-n PF-05089771 is a selective, small-molecule Na v 1.7 and Na v 1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic . [ 1 ] [ 2 ] [ 3 ] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia .